A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-24

Study Completion Date

2022-12-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is designed to compare the rate and extent of absorption of four different formulations of zavegepant. 52 healthy male and female volunteers will receive a single dose of each formulation at least 7 days apart over a period of about 7 weeks and the amount of drug in their blood will be assessed over the 24 hour period after each dose.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)

NCT03662191

Healthy Volunteers

COMPLETED PHASE1

A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling

NCT05948085

Healthy

COMPLETED PHASE1

A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults

NCT06347861

Healthy

COMPLETED PHASE1

A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults

NCT06911788

Healthy Participants

COMPLETED PHASE1

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Zongertinib in the Blood

NCT06028464

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 1, single centre, open-label, single dose, 4-period, crossover study designed to compare the pharmacokinetics (PK) of zavegepant from three Test products and a Reference product (treatment D).

52 male and female healthy volunteers will be randomly assigned to one of 4 treatment sequences: ACBD, CDAB, BADC, and DBCA.

In each period, subjects will receive one of the following: Treatment A, B, C, or D on Day 1, followed by 24 hours of PK and safety assessments. On Day 2 subjects will be discharged from the clinical site and instructed to return after at least a 7 day washout time has passed for subsequent periods of treatment.

The study will include a screening visit from Day -28 to Day -2. Eligible subjects will be admitted to the clinical site on Day -1 and will be confined until completion of the assessments on Day 2. There will be a washout period of at least 7 days between doses. Study Exit procedures will be performed after the last assessment on the morning of Day 2 of Period 4. Study Exit procedures will be performed as soon as possible in case of Early Termination.

The total duration of study participation for each subject from Screening through Study Exit is anticipated to be approximately 6.5 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Biological Availability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized, open-label, single dose, 4-period cross-over, comparative bioavailability study in healthy volunteer participants.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

All investigators, Sponsor personnel, clinical monitors, independent PK analyst, and participants in the study will be unblinded to the treatment allocation as the primary and secondary endpoints are based on objective criteria of laboratory findings.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sequence 1

Period 1 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 2 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 3 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 4 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D).

Group Type EXPERIMENTAL

Zavegepant 100mg non-enteric coated soft gel capsule

Intervention Type DRUG

Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule

Zavegepant 100mg immediate release tablet

Intervention Type DRUG

Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet

Zavegepant 2 x 100mg immediate release tablets

Intervention Type DRUG

2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg

Zavegepant 4 x 25mg enteric coated soft gel capsule

Intervention Type DRUG

Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg

Sequence 2

Period 1 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 2 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 3 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 4 - Single zavegepant 100mg immediate release tablet (Treatment B).

Group Type EXPERIMENTAL

Zavegepant 100mg non-enteric coated soft gel capsule

Intervention Type DRUG

Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule

Zavegepant 100mg immediate release tablet

Intervention Type DRUG

Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet

Zavegepant 2 x 100mg immediate release tablets

Intervention Type DRUG

2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg

Zavegepant 4 x 25mg enteric coated soft gel capsule

Intervention Type DRUG

Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg

Sequence 3

Period 1 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 2 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 3 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 4 - Two zavegepant 100mg immediate release tablets (Treatment C).

Group Type EXPERIMENTAL

Zavegepant 100mg non-enteric coated soft gel capsule

Intervention Type DRUG

Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule

Zavegepant 100mg immediate release tablet

Intervention Type DRUG

Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet

Zavegepant 2 x 100mg immediate release tablets

Intervention Type DRUG

2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg

Zavegepant 4 x 25mg enteric coated soft gel capsule

Intervention Type DRUG

Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg

Sequence 4

Period 1 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 2 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 3 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 4 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A).

Group Type EXPERIMENTAL

Zavegepant 100mg non-enteric coated soft gel capsule

Intervention Type DRUG

Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule

Zavegepant 100mg immediate release tablet

Intervention Type DRUG

Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet

Zavegepant 2 x 100mg immediate release tablets

Intervention Type DRUG

2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg

Zavegepant 4 x 25mg enteric coated soft gel capsule

Intervention Type DRUG

Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zavegepant 100mg non-enteric coated soft gel capsule

Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule

Intervention Type DRUG

Zavegepant 100mg immediate release tablet

Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet

Intervention Type DRUG

Zavegepant 2 x 100mg immediate release tablets

2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg

Intervention Type DRUG

Zavegepant 4 x 25mg enteric coated soft gel capsule

Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Treatment A Treatment B Treatment C Treatment D

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must provide Informed Consent Form (ICF) obtained prior to the conduct of any study activities.
* Healthy Male or female participants at least 18 and less than 56 years of age,
* Participants must be Non-smokers and not have used any nicotine-containing products for 3 months prior to screening.
* Body Mass Index (BMI) \>18.5 and \<30.0kg/m2 and body weight ≥ 50.0kg for males and ≥ 45.0kg for females.
* All females participants must not be breastfeeding and have a negative urine pregnancy test at Screening.
* Females of childbearing potential must be willing to use acceptable contraceptive methods throughout the study and for 30 days after the last study drug administration.
* Male participants with a female partner of childbearing potential must be willing to use acceptable contraceptive methods from the first study drug administration until at least 90 days after the last study drug administration.

Exclusion Criteria

* Current diagnosis of viral hepatitis or a history of liver disease.
* Any history of seizure disorder (e.g., epilepsy) other than a single childhood febrile seizure.
* Current or recent (within 3 months of the first study drug administration) gastrointestinal disease that may interfere with drug absorption.
* Prior gastrointestinal surgery that interferes with absorption and motility (e.g., gastric bypass, duodenectomy or gastric banding).
* History of drug or alcohol abuse.
* History of anaphylaxis, a documented hypersensitivity reaction, or a clinically significant reaction to any drug or to any of the excipient supporting the zavegepant formulations.
* Donation of plasma within 7 days prior to dosing, or donation or loss of blood (excluding volume drawn at Screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to dosing.
* Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the dosing, extended to 90 days for biological products.
* Inability or difficulty to swallow tablets or capsules.
* Subjects with any clinically significant abnormality or significant abnormal laboratory test results found during medical screening or Day-1. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody during screening.
* Inadequate renal function - estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Disease (MDRD) study equation ≤ 60 mL/min/1.73 m2 at Screening.
* Any of the following laboratory parameters greater than the upper limit of normal (ULN) values at Screening or Baseline (Day -1): alkaline phosphatase (ALP) aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, and indirect bilirubin, and alkaline phosphatase.
* Any clinically significant abnormalities on 12-lead ECG or blood pressure (BP) at Screening or Baseline (Day -1) visits.
* Any clinically significant abnormal haematological laboratory test values at Screening or Baseline (Day -1) visits.
* Positive test for COVID-19 performed on Day -1 of each period.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes